Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Head & Neck 2Genitourinary 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 86Lung Neoplasms 32Small Cell Lung Carcinoma 18Melanoma 17Mesothelioma 13Neoplasms 11Colorectal Neoplasms 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 7Mesothelioma, Malignant 7Carcinoma, Transitional Cell 7Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Endometrial Neoplasms 5Carcinoma, Hepatocellular 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Kidney Neoplasms 4Brain Neoplasms 4Carcinoma, Merkel Cell 3Skin Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2

Interventions

pembrolizumab 12Nivolumab 4fludarabine 3Gemcitabine 3Drug Therapy 3Cisplatin 3spartalizumab 2budigalimab 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zenocutuzumab 1venetoclax 1ulixertinib 1tocilizumab 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1neratinib 1milademetan 1margetuximab 1erdafitinib 1entrectinib 1cobimetinib 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Ipilimumab × Thoracic × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡